NASDAQ
PYXS

Pyxis Oncology Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Pyxis Oncology Inc Stock Price

Vitals

Today's Low:
$2.16
Today's High:
$2.35
Open Price:
$2.28
52W Low:
$1.1
52W High:
$6.92
Prev. Close:
$2.3
Volume:
129792

Company Statistics

Market Cap.:
$101.78 million
Book Value:
3.689
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-31.37%
Return on Equity TTM:
-55.38%

Company Profile

Pyxis Oncology Inc had its IPO on 2021-10-08 under the ticker symbol PYXS.

The company operates in the Healthcare sector and Biotechnology industry. Pyxis Oncology Inc has a staff strength of 72 employees.

Stock update

Shares of Pyxis Oncology Inc opened at $2.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.16 - $2.35, and closed at $2.22.

This is a -3.48% slip from the previous day's closing price.

A total volume of 129,792 shares were traded at the close of the day’s session.

In the last one week, shares of Pyxis Oncology Inc have slipped by -4.31%.

Pyxis Oncology Inc's Key Ratios

Pyxis Oncology Inc has a market cap of $101.78 million, indicating a price to book ratio of 0.2176 and a price to sales ratio of 0.

In the last 12-months Pyxis Oncology Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-103733000. The EBITDA ratio measures Pyxis Oncology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pyxis Oncology Inc’s operating margin was 0% while its return on assets stood at -31.37% with a return of equity of -55.38%.

In Q2, Pyxis Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Pyxis Oncology Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pyxis Oncology Inc’s profitability.

Pyxis Oncology Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3966. Its price to sales ratio in the trailing 12-months stood at 0.

Pyxis Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$175.23 million
Total Liabilities
$9.23 million
Operating Cash Flow
$0
Capital Expenditure
$2.26 million
Dividend Payout Ratio
0%

Pyxis Oncology Inc ended 2024 with $175.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $175.23 million while shareholder equity stood at $145.28 million.

Pyxis Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $9.23 million in other current liabilities, 39000.00 in common stock, $-247579000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.90 million and cash and short-term investments were $142.66 million. The company’s total short-term debt was $527,000 while long-term debt stood at $0.

Pyxis Oncology Inc’s total current assets stands at $149.30 million while long-term investments were $0 and short-term investments were $116.77 million. Its net receivables were $0 compared to accounts payable of $1.31 million and inventory worth $0.

In 2024, Pyxis Oncology Inc's operating cash flow was $0 while its capital expenditure stood at $2.26 million.

Comparatively, Pyxis Oncology Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.22
52-Week High
$6.92
52-Week Low
$1.1
Analyst Target Price
$10.25

Pyxis Oncology Inc stock is currently trading at $2.22 per share. It touched a 52-week high of $6.92 and a 52-week low of $6.92. Analysts tracking the stock have a 12-month average target price of $10.25.

Its 50-day moving average was $2.42 and 200-day moving average was $2.37 The short ratio stood at 5.77 indicating a short percent outstanding of 0%.

Around 3092.5% of the company’s stock are held by insiders while 2623.6% are held by institutions.

Frequently Asked Questions About Pyxis Oncology Inc

The stock symbol (also called stock or share ticker) of Pyxis Oncology Inc is PYXS

The IPO of Pyxis Oncology Inc took place on 2021-10-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$5.32
0.03
+0.57%
$32.76
5.05
+18.22%
$4.5
-0.12
-2.6%
$0.07
-0.01
-10.03%
$138.4
-9.05
-6.14%
Airgain Inc (AIRG)
$4.45
0.05
+1.14%
$7.04
-0.18
-2.49%
$13.01
0.03
+0.23%
$0.22
-0.04
-14.79%
$1.75
0.14
+8.7%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company’s antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Address

35 Cambridgepark Drive, Cambridge, MA, United States, 02140